|
US2003018018A1
|
|
Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
|
|
US6258802B1
|
|
Corticoid therapy
|
|
CA2268211A1
|
|
Control of selective estrogen receptor modulators
|
|
WO9943785A1
|
|
Derivation of cells and tissues from embryonic pre-stem cells for transplantation therapies
|
|
BR9804054A
|
|
Antiprogestin deposit therapy method.
|
|
US6653297B1
|
|
Control of selective estrogen receptor modulators
|
|
US5898032A
|
|
Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
|
|
EP0811382A1
|
|
Mammography method
|
|
US5691314A
|
|
Adjunctive therapy
|
|
AU5175996A
|
|
Glycoconjugate inhibitors of human sperm-egg binding
|
|
RU2181598C2
|
|
Recovery of tonic secretion of ovarian estrogen for prolonged therapeutic schemes
|
|
US5658884A
|
|
Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
|
|
US5824286A
|
|
Mammography method
|
|
ZA9407572B
|
|
Contraceptive compositions
|
|
US5552394A
|
|
Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
|
|
US5639656A
|
|
Antibodies reactive with biological markers of benign prostate hyperplasia
|
|
US5681817A
|
|
Treatment of ovarian estrogen dependent conditions
|
|
US5622943A
|
|
Minimizing progestin associated breakthrough bleeding
|
|
US5468736A
|
|
Hormone replacement therapy
|
|
US5516769A
|
|
Method of inhibiting fertilization
|
